CLAIMS

1. Compound of formula (I)



(I),

in which

R^1 represents hydrogen or fluorine,

L^1 represents ethane-1,2-diyl or 1,4-phenylene,

and

A represents a group of the formula



in which

* denotes the respective point of attachment to the remainder of the molecule,

L^3 represents a bond, -O-, $-CH_2-$, $-CH_2-CH_2-$ or -CH=CH-,

R^{3C} represents a substituent selected from the group consisting of fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, difluoromethyl, trifluoromethyl, (C_1-C_4)-alkoxy, difluoromethoxy and trifluoromethoxy,

and

R^{3D} represents a substituent selected from the group consisting of hydrogen, fluorine, chlorine, bromine, cyano, (C_1-C_4)-alkyl, difluoromethyl, trifluoromethyl, (C_1-C_4)-alkoxy, difluoromethoxy and trifluoromethoxy

and salts, solvates and solvates of the salts thereof.

2. Compound of formula (I) according to Claim 1, in which

R^1 represents hydrogen or fluorine,

L^1 represents ethane-1,2-diyl or 1,4-phenylene,
and

A represents a group of the formula



in which

* denotes the respective point of attachment to the remainder of the molecule,

L^3 represents a bond, $-CH_2-CH_2-$ or -CH=CH-,

R^{3C} represents fluorine, chlorine, methyl or trifluoromethyl,

and

R^{3D} represents hydrogen, fluorine, chlorine, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy,

and salts, solvates and solvates of the salts thereof.

3. Compound of formula (I) according to Claim 1 or Claim 2, in which

R^1 represents hydrogen or fluorine,

L^1 represents ethane-1,2-diyl or 1,4-phenylene,

and

A represents a group of the formula



in which

* denotes the respective point of attachment to the remainder of the molecule,

L^3 represents a bond, $-CH_2-CH_2-$ or -CH=CH-,

R^{3C} represents fluorine, chlorine, methyl or trifluoromethyl,

and

R^{3D} represents hydrogen, fluorine, chlorine, cyano, methyl, trifluoromethyl or trifluoromethoxy,

and salts, solvates and solvates of the salts thereof.

4. Compound of formula (I) according to any one of Claims 1 to 3, in which

R^1 represents hydrogen or fluorine,

L^1 represents ethane-1,2-diyl or 1,4-phenylene,

and

A represents a group of the formula



in which

* denotes the respective point of attachment to the remainder of the molecule,

L^3 represents a bond or $-CH_2-CH_2-$,

R^{3C} represents chlorine,

and

R^{3D} represents hydrogen, fluorine or trifluoromethyl,

and salts, solvates and solvates of the salts thereof.

5. 5-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula



and salts, solvates and solvates of the salts thereof.

6. 5-{(4-carboxybutyl)[2-(2-{[3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula



and salts, solvates and solvates of the salts thereof.

7. Process for preparing a compound of formula (I) as defined in any one of Claims 1 to 4, the process comprising either

[A] reacting a compound of formula (II)



(II),

in which R^1 and L^1 are as defined in any one of Claims 1 to 4

and

T^1 and T^2 are identical or different and represent $(C_1$-$C_4)$-alkyl,

in the presence of a base with a compound of formula (III)



(III),

in which A is as defined in any one of Claims 1 to 4

and

X^1 represents a leaving group

or

[B] reacting a compound of formula (IV)



(IV),

in which R^1 and A are as defined in any one of Claims 1 to 4

and

T^2 represents $(C_1\text{-}C_4)$-alkyl,

in the presence of a base with a compound of formula (V)



(V),

in which L^1 is as defined in any one of Claims 1 to 4,

T^1 represents $(C_1\text{-}C_4)$-alkyl,

and

X^2 represents a leaving group

and then converting the respective resulting compound of formula (VI)



(VI),

in which R^1, A, L^1, T^1 and T^2 are as defined above,

by hydrolysis of the ester groupings $-C(O)OT^1$ and $-C(O)OT^2$ into the corresponding dicarboxylic acid of the formula (I).

8. Process according to Claim 7, wherein the resulting compound of formula (I) is separated into its enantiomers and/or diastereomers and/or converted with the appropriate (i) solvents and/or (ii) bases or acids into their solvates, salts and/or solvates of the salts.

9. Process according to Claim 7 or Claim 8, wherein X^1 is selected from the group consisting of chlorine, bromine, iodine, mesylate, triflate and tosylate.

10. Process according to Claim 7 or Claim 8, wherein X^2 is selected from the group consisting of chlorine, bromine, iodine, mesylate, triflate and tosylate.

11. A compound prepared by the process according to any one of Claims 7 to 10.

12. Compound according to any one of Claims 1 to 6 or 11 for use in the treatment and/or prevention of a disease.

13. Use of a compound as defined in any one of Claims 1 to 6 or 11 for the preparation of a medicament for the treatment and/or prevention of primary and secondary forms of pulmonary hypertension, heart failure, angina pectoris, hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and/or arteriosclerosis.

14. Medicament comprising a compound according to any one of Claims 1 to 6 or 11 in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries.

15. Medicament comprising a compound according to any one of Claims 1 to 6 or 11 in combination with one or more further active compounds selected from the group consisting of organic nitrates, NO donors, PDE 5 inhibitors, prostacyclin analogues, IP receptor agonists, endothelin receptor antagonists, guanylate cyclase stimulators, tyrosine kinase inhibitors, anti-obstructive agents, anti-inflammatory and/other immunsuppressive agents, antithrombotic agents, agents for lowering blood pressure and agents that alter fat metabolism.

16. Medicament according to Claim 14 or Claim 15 for use in the treatment and/or prevention of primary and secondary forms of pulmonary hypertension, heart failure, angina pectoris, hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and/or arteriosclerosis.